iBio, Inc.IBIOEarnings & Financial Report
iBio, Inc. is a clinical-stage biotechnology company that leverages its proprietary plant-based protein expression platform to develop novel biopharmaceuticals, including vaccines, antibody therapies, and treatments for infectious diseases, oncology, and fibrotic conditions. Its core operating market is North America, serving global biopharmaceutical and public health stakeholders.
IBIO Q2 FY2026 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-9.4M
Net Profit
$-9.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.09
iBio, Inc. Q2 FY2026 Financial Summary
iBio, Inc. reported revenue of $0 for Q2 FY2026, with a net profit of $-9.0M (down 106.1% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-9.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q2 FY2026 |
iBio, Inc. Annual Revenue by Year
iBio, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $0).
iBio, Inc. Quarterly Revenue & Net Profit History
iBio, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $0 | — | $-9.0M | N/A |
| Q1 FY2026 | $100.0K | — | $-5.7M | -5720.0% |
| Q3 FY2025 | $0 | — | $-4.9M | N/A |
| Q2 FY2025 | $200.0K | — | $-4.4M | -2182.0% |
| Q1 FY2025 | $0 | — | $-4.0M | N/A |
| Q2 FY2024 | $0 | — | $-8.2M | N/A |
| Q1 FY2024 | $50.0K | — | $-5.7M | -11492.0% |
| Q4 FY2023 | $0 | — | $-6.0M | N/A |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $50000 | $0 | $0 | $200000 | $0 | $100000 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $41.2M | $37.7M | $34.0M | $24.5M | $21.7M | $19.1M | $64.2M | $64.4M |
| Liabilities | $25.8M | $24.5M | $24.8M | $6.8M | $7.8M | $7.7M | $8.1M | $7.8M |
| Equity | $15.4M | $13.2M | $9.2M | $17.8M | $13.9M | $11.4M | $56.0M | $56.6M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.0M | $-5.3M | $-4.7M | $-3.7M | $-3.9M | $-3.1M | $-5.7M | $-5.2M |